Free
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma – Monday, June 16, 2025
Free
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis – Tuesday, October 14, 2025
Free
Using Mass Spectrometry Assays in Multiple Myeloma: Where Do We Stand? – Tuesday, April 22, 2025
Free
Highlights from IMS 2025: A Focus on CELMoDs – Monday, October 20, 2025
Free
Characterization of clonal dynamics using duplex sequencing in donor-recipient pairs decades after hematopoietic cell transplantation – Tuesday, January 21, 2025
Free
CMV recommendations ECIL-10 – Thursday, June 26, 2025
Free
Periodontal Disease Explained: Classification, Treatment, and Hematologic Patient Care – Monday, September 22, 2025
Free
Post-IACH 2025 Roundtable Debate – Monday, October 13, 2025
Free
Evidence-Based Practice and Research Literacy for Nurses in Hematology and Bone Marrow Transplant – Thursday, January 8, 2026
Free
Role of the Microbiota in GVHD and Hematology More Broadly – Wednesday, January 14, 2026
Free
Frontline therapy of CLL: where do we stand? – Wednesday, October 1, 2025
Free
JOURNAL CLUB – Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE – Monday, February 10, 2025
Free
CLL Academy – Highlights of CLL Data Presented at the ASH 2025 – Tuesday, December 16, 2025
Free
Multiple Myeloma Academy – Educating Patients for Better Outcomes – Monday, November 24, 2025
Free
Multiple Myeloma Academy – Bispecific Antibodies in Multiple Myeloma: Practical Strategies for Safe and Effective Delivery – Thursday, November 20, 2025
Free
A case on chronic GVHD – Wednesday, September 3, 2025
Free
Multiple Myeloma Academy – COMy 2025 – The Future of Myeloma Therapy – Thursday, August 28, 2025
Free
Multiple Myeloma Academy – COMy 2025 – From Thalidomide to CELMoDs: A Clinical Journey – Monday, August 25, 2025
Free
CLL Academy – IACH Journal Club – Zanubrutinib and Venetoclax for Patients With Treatment-Na¨ ıve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results – Tuesday, July 8, 2025
Free
